← Back
$RPRX All transactions

Royalty Pharma plc

▼ SELL 10b5-1 Plan

$ Value

$822K

Shares

20,000

Price

$41

Filed

Feb 2

Insider

Name

Urist Marshall

Title

EVP, Research & Investments

CIK

0001838139

Roles

Officer

Transaction Details

Transaction Date

2026-01-30

Code

S

Table

Non-Derivative

Ownership

Indirect

Equity Swap

No

Shares After

Footnotes

All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on September 16, 2025. | The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.88 to $41.28 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Filing Info

Accession No.

0001838139-26-000010

Form Type

4

Issuer CIK

0001802768

Urist Marshall's History

Date Ticker Type Value
2026-02-11 RPRX A $0
2026-01-30 RPRX $822K
2026-01-23 RPRX $805K
2026-01-16 RPRX $790K
2026-01-09 RPRX $816K
2026-01-02 RPRX $770K
2025-12-26 RPRX $786K
2025-12-19 RPRX $768K
2025-12-16 RPRX $766K
2025-12-05 RPRX $914K

Other Insiders at RPRX (90d)

Insider Bought Sold Last
Legorreta Pablo G.
CEO, Chairman of the Board
2026-02-11
Bassler Bonnie L 2026-03-31
Hite Christopher
EVP & Vice Chairman
2026-02-11
Coyne Terrance P.
EVP & CFO
$16.8M 2026-04-01
Urist Marshall
EVP, Research & Investments
2026-02-11